GT Biopharma (GTBP) had the highest return between September 1, 2017 and March 31, 2018 by a US stock, returning 3,313,165.3%.
| ASSET | DATE | % RETURN |
|---|---|---|
GT Biopharma (GTBP) | 9/1/2017 - 3/31/2018 | 3,313,165.31% |
Avalon GloboCare (ALBT) | 9/1/2017 - 3/31/2018 | 2,113,935.09% |
Delcath Systems (DCTH) | 9/1/2017 - 3/31/2018 | 6,594.52% |
Quantum Computing (QUBT) | 9/1/2017 - 3/31/2018 | 5,900% |
SurgePays (SURG) | 9/1/2017 - 3/31/2018 | 4,605.88% |
TON Strategy (TONX) | 9/1/2017 - 3/31/2018 | 1,218.18% |
Gyre Therapeutics (GYRE) | 9/1/2017 - 3/31/2018 | 679.46% |
Madrigal Pharmaceuticals (MDGL) | 9/1/2017 - 3/31/2018 | 588.13% |
Anixa Biosciences (ANIX) | 9/1/2017 - 3/31/2018 | 464.71% |
Avalo Therapeutics (AVTX) | 9/1/2017 - 3/31/2018 | 464.47% |
Galaxy Digital (GLXY) | 9/1/2017 - 3/31/2018 | 426.38% |
Nektar Therapeutics (NKTR) | 9/1/2017 - 3/31/2018 | 402.89% |
Enphase Energy (ENPH) | 9/1/2017 - 3/31/2018 | 402.2% |
InMed Pharmaceuticals (INM) | 9/1/2017 - 3/31/2018 | 382.51% |
eGain (EGAN) | 9/1/2017 - 3/31/2018 | 354.29% |
Rocket Pharmaceuticals (RCKT) | 9/1/2017 - 3/31/2018 | 350.72% |
Gravity (GRVY) | 9/1/2017 - 3/31/2018 | 338.54% |
CASI Pharmaceuticals (CASI) | 9/1/2017 - 3/31/2018 | 334.38% |
Viking Therapeutics (VKTX) | 9/1/2017 - 3/31/2018 | 316.19% |
argenx NV ADR (ARGX) | 9/1/2017 - 3/31/2018 | 289.35% |
Viewbix Inc Common Stock (VBIX) | 9/1/2017 - 3/31/2018 | 274.23% |
AnaptysBio (ANAB) | 9/1/2017 - 3/31/2018 | 272.38% |
TSS, Inc Common Stock (TSSI) | 9/1/2017 - 3/31/2018 | 268.52% |
Canopy Growth (CGC) | 9/1/2017 - 3/31/2018 | 260.37% |
Aurora Cannabis (ACB) | 9/1/2017 - 3/31/2018 | 259.9% |
